Apr 13, 2026 07:32AM NorthStrive transfers EL-32 cell bank to US facility for manufacturing

Apr 8, 2026 07:31AM PMGC Holdings fully utilizes $20M equity financing facility

Apr 2, 2026 04:06PM PMGC Holdings forms defense tech subsidiary targeting drones

Mar 30, 2026 07:05AM PMGC Holdings grows assets 43% to $12.87 million through acquisitions

Mar 10, 2026 07:31AM PMGC starts preclinical study of muscle preservation therapy EL-32

Feb 10, 2026 04:40PM PMGC subsidiary licenses animal biologic technology to Modulant Biosciences

Feb 4, 2026 04:30PM NorthStrive extends AI drug discovery Phase III timeline to Q2 2026

Feb 3, 2026 07:30AM PMGC Holdings acquires SVM Machining for $2.25 million base price

Jan 6, 2026 07:31AM PMGC Holdings acquires stake in micro nuclear reactor developer

Dec 22, 2025 07:30AM AGA Precision Systems earns AS9100 aerospace certification

Dec 17, 2025 07:31AM NorthStrive Biosciences begins Phase III of AI drug discovery program

Nov 26, 2025 06:08AM PMGC Holdings (ELAB) files for 5M share offering by selling stockholders

Oct 20, 2025 07:31AM PMGC Holdings reports $711,000 sales backlog at AGA Precision subsidiary

Oct 16, 2025 06:05AM PMGC Holdings (ELAB) files for 5M share offering by selling stockholders

Sep 4, 2025 09:55AM Northstrive completes phase II of AI drug development program

Aug 22, 2025 01:49PM PMGC Holdings raises $1.67 million through warrant exercise agreement

Jul 30, 2025 07:45AM PMGC Holdings terminates electronics deal, shifts focus to CNC manufacturing

Jun 24, 2025 08:30AM PMGC Holdings (ELAB) to Acquire CNC Aerospace Manufacturer

Jun 16, 2025 08:00AM PMGC Holdings (ELAB) Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years

Jun 9, 2025 08:00AM PMGC Holdings (ELAB) to Acquire Profitable U.S.-Based Electronics Manufacturing Company

May 22, 2025 08:17AM Northstrive Biosciences (ELAB) completes Phase 1 review for EL-22

Apr 29, 2025 08:02AM Northstrive Biosciences (ELAB) Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Apr 24, 2025 08:01AM Northstrive Biosciences (ELAB) Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 with GLP-1 Receptor Agonist for Obesity Treatment

Apr 10, 2025 08:01AM Northstrive Biosciences (ELAB) Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Mar 21, 2025 02:41PM PMGC Holdings (ELAB) Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

Mar 21, 2025 08:00AM PMGC Holdings (ELAB) Announces Share Repurchases from Existing Shareholders

Mar 10, 2025 08:01AM PMGC's (ELAB) Northstrive Biosciences Schedules Pre-IND Meeting with FDA for EL-22

Mar 6, 2025 09:01AM PMGC Holdings (ELAB) Announces 1:7 Reverse Share Split

Jan 27, 2025 09:01AM PMGC Holdings (ELAB) Receives $1.9M in Gross Proceeds from Warrant Inducement with Institutional Investors

Jan 27, 2025 06:06AM PMGC Holdings (ELAB) Files $100M Mixed Shelf

Jan 24, 2025 08:03AM PMGC Holdings (ELAB): Northstrive Biosciences to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

Jan 2, 2025 03:59PM PMGC Holdings (ELAB) Embarks on Bold Growth Strategy

Jan 2, 2025 08:01AM Carmell Corporation (CTCX) to Acquire Elevai Skincare

Jan 2, 2025 08:01AM Carmell Corporation (CTCX) to Acquire Elevai Skincare

Dec 20, 2024 07:32AM Elevai Labs (ELAB) Announces Anticipated Name Change to PMGC Holdings, Redomicile to Nevada

Dec 9, 2024 08:03AM Elevai Labs (ELAB) Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

Oct 22, 2024 09:55AM Elevai (ELAB) Engages Leading Contract Research Organization to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

Oct 21, 2024 07:30AM Elevai Biosciences (ELAB) Highlights Past Positive Preclinical Data Showing Potential of EL-32

Oct 3, 2024 07:31AM Elevai Biosciences, a Subsidiary of Elevai Labs (ELAB), Expands Patent Portfolio

Oct 2, 2024 08:30AM Elevai Labs (ELAB) Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

Sep 23, 2024 08:45AM Elevai Labs (ELAB) Prices 28.57M Share Offering at $0.38/sh

Sep 16, 2024 06:53AM Elevai Labs (ELAB) Files for 28.37M Share and Warrant Offering

Sep 10, 2024 07:31AM Elevai Labs' (ELAB) Elevai Skincare Reports Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Sep 3, 2024 07:30AM Elevai Labs (ELAB) Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Aug 28, 2024 07:30AM Elevai Labs (ELAB) Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology

Aug 26, 2024 07:30AM Elevai Labs (ELAB) Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

Aug 19, 2024 09:01AM Elevai Labs (ELAB) Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications